Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook missed Wall Street’s expectations.

The stock fell 4.7% to $39.90 in after-hours trading on Monday. Shares have risen 73% year-to-date through Monday’s market close.

The telehealth-consultation platform on Monday posted a profit of $49.5 million, or 20 cents a share, compared with $11.1 million, or 5 cents a share, a year earlier. Analysts polled by FactSet expected 12 cents a share.

Revenue more than doubled to $586 million from $278.2 million a year ago. Analysts polled by FactSet expected $538.6 million.

The San Francisco-based company now has almost 2.4 million subscribers, up 38% from the year-ago period. Average monthly online revenue per subscriber rose to $84 from $55.

For the second quarter, the company expects revenue between $530 million to $550 million, compared with analyst expectations of $564.6 million.

For the full year, the company maintained its previous guidance for sales of $2.3 billion to $2.4 billion. Analysts were looking for $2.33 billion.

The results come amid a rapidly changing landscape for weight-loss drugs. Hims in February said it would stop offering compounded semaglutide, a version of the active ingredient in weight-loss drugs Wegovy and Ozempic, after the first quarter. At the time, Novo Nordisk said the Food and Drug Administration determined that the shortage of Wegovy and Ozempic had been resolved.

However Hims has found ways to expand its offerings. It teamed up with Novo Nordisk in April to sell Wegovy in the U.S. The platform also last month expanded its offerings to generic liraglutide and tirzepatide, the name of Eli Lilly’s weight-loss drug Zepbound and diabetes drug Mounjaro.

Hims Chief Executive Andrew Dudum said he expects wider collaboration across the industry, including pharmaceutical companies, over time.

Hims earlier Monday named a former Amazon.com executive, Nader Kabbani, as its chief operating officer, an appointment that comes as the company is looking to expand access to its offerings, which currently includes treatments for sexual health, hair loss and weight management. While at Amazon, Kabbani led the launch of the online retailer’s pharmacy business and acquisition of PillPack, which presorts medications and ships them to homes.